Sarcospan-deficient mouse as a model for clinical disorders associated with sarcospan mutations
US6207878A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Oct 21, 1999 |
| Grant date | Mar 27, 2001 |
| Priority date | — |
| Expiry date | Oct 21, 2019 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2800/30
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Disclosed is a transgenic knockout mouse whose genome has a homozygous disruption in its endogenous sarcospan gene, wherein the disruption prevents the synthesis of functional sarcospan in cells of the mouse. The mouse is characterized as exhibiting from 1.4 to 6.8 fold larger epididymal fat pad deposits as compared to the epididymal fat pad deposits of a wild type mouse. Methods for production of the mouse are presented. Also disclosed are cells derived from the transgenic knockout mouse. The mouse can be used in a method for identifying therapeutic agents for the treatment of an individual diagnosed with a metabolic disorder associated with a reduction or loss of expression of wild-type sarcospan. An example of such a disorder is weight gain in the individual associated with a reduction or loss of expression of wild-type sarcospan. These specific methods are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.